Breast Cancer Awareness Month: The Fight for Accessible Medical Care for Women with Disabilities
October 07, 2024 11:53 ET
|
D S Simon
HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Accessing healthcare can be a daunting challenge for women with mobility disabilities. From inaccessible patient rooms and exam tables to mammography...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust
October 04, 2024 15:00 ET
|
Epi One
New York, NY, Oct. 04, 2024 (GLOBE NEWSWIRE) -- In a world still reeling from the Theranos scandal, a new beacon of hope in cancer detection is rising – and this time, it's inviting the world to...
South Africa Construction Industry Report 2024: Output Expected to Reach ZAR 190.66 Billion by 2028, Driven by PPIs, Infrastructure Development, and Technological Advancements
October 02, 2024 10:39 ET
|
Research and Markets
Dublin, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The "South Africa Construction Industry Databook Series - Market Size & Forecast by Value and Volume (area and units), Q2 2024 Update" report has been...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
October 01, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
September 30, 2024 08:00 ET
|
Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
September 27, 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...
Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET
|
Urteste S.A.
Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT), a biotechnology company...